

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K/A

Amendment No.1

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **May 26, 2016 (May 25, 2016)**

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

Ireland

(State or other jurisdiction
of incorporation)

001-35299

(Commission
File Number)

98-1007018

(IRS Employer
Identification No.)

**Connaught House, 1 Burlington Road
Dublin 4, Ireland**

(Address of principal executive offices)

(Zip Code)

(Registrant's telephone number, including area code): **+ 353-1-772-8000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Explanatory Note:

Alkermes plc (the "Company") hereby amends Item 5.02(d) of its Current Report on Form 8-K dated May 26, 2016 for the purpose of describing a grant made to a director in connection with the event triggering such Item 5.02(d).

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d) On September 14, 2016, in connection with the election of Nancy L. Snyderman, M.D. as a Class I director of the Company on May 26, 2016 and consistent with the "Director Compensation" section of the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 13, 2016, the compensation committee of the board of directors of the Company granted Dr. Snyderman a new director grant of 27,400 non-qualified stock options that will vest in equal parts over three years and a pro-rated annual grant of 16,200 non-qualified stock options that become exercisable in full on September 14, 2017, in each case, with an exercise price of \$47.65.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALKERMES PLC

Date: September 20, 2016

By: /s/ James M. Frates

James M. Frates
Senior Vice President and Chief

